Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Sep 29 2025

Full Issue

Viewpoints: What 25 Years Of Mifepristone In The US Has Brought; Actions That Will Lower Drug Costs

Opinion writers discuss these public health issues.

Stat: Celebrating Mifepristone, A Hero In Modern Abortion Access, On Its 25th Anniversary In The U.S.

When the Food and Drug Administration approved mifepristone, the abortion pill, on Sept. 28, 2000, none of us working on expanding access to reproductive health care could have imagined the future we find ourselves in 25 years later. From the fall of Roe in 2022 and the subsequent banning or restriction of abortion in 19 states, to South Carolina’s recent efforts to include some forms of birth control in its total abortion ban, access to the basic medical care and medications that allow us to control our reproductive destinies is hanging by a thread. In the midst of this reproductive health care apocalypse, mifepristone is proving itself to be a hero in the fight for abortion access. (Elisa Wells, 9/28)

The Washington Post: How Big Pharma Wants To Lower Drug Prices

The biopharmaceutical industry is responding to Trump’s call to put America first by announcing three major actions to lower drug costs for patients, protect medical innovation and strengthen the nation’s leadership in life sciences. (Steve Ubl, 9/29)

St. Louis Post-Dispatch: Trump Cuts Food Program — Then Cuts Hunger Survey. It’s Part Of A Pattern.

President Donald Trump’s “Big Beautiful Bill” is anything but for the nation’s poorest families. Among the numerous cruel elements to the new spending plan are food-program cuts that are expected to increase “food insecurity” — also known as hunger — for millions of Americans, including children. What terrible optics going into the midterm election season. But no worries. Trump’s administration this month announced how it intends to address the politically inconvenient specter of coddling billionaires at the expense of impoverished Americans who will go hungry: It’s ending the longstanding hunger survey that counts them. (9/28)

The Boston Globe: Trump Blames Pregnant Women For Autism

The Trump administration’s targeting of women’s behavior as the basis for autism evokes the disgraceful mid-20th-century era of so-called refrigerator mothers, when the medical establishment widely believed and falsely claimed that autism in children was caused by cold and emotionally distant mothers. (Renee Graham, 9/28)

Stat: How The FDA Can Bring More Medicine Manufacturing To The U.S. 

America’s role in advancing science, investing in domestic manufacturing, and protecting public health is at a pivotal moment. Scientific discoveries are creating unprecedented opportunities, and the choices government agencies make today will determine how quickly those innovations reach patients. By modernizing how we develop and manufacture lifesaving therapies here at home, we can bet on ourselves and accelerate delivery to the people who need them most. (Jeffrey Francer and Victor Cruz, 9/29)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF